PharmiWeb.com - Global Pharma News & Resources

Clinical research - Press Releases

Date Title Company
09-Jul-2024 Pascal Piedbois, MD, PhD joins One2Treat as Chief Medical Officer to advance patient-centric innovation in clinical trial design and market access One2Treat
08-Jul-2024 Spur provides update on FLT201 and planned Phase III clinical trial Syncona Limited
05-Jul-2024 CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe CSL
05-Jul-2024 CNX Therapeutics Announces CFO Transition: Olga Lund to depart, Claire Masterson Joins as new CFO CNX Therapeutics
05-Jul-2024 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status HUTCHMED
05-Jul-2024 Launch of Phase 3 clinical trial with Nefecon in Japan Calliditas Therapeutics
05-Jul-2024 Researchers map the effects of all potential changes in key cancer gene Francis Crick Institute
05-Jul-2024 HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status HUTCHMED
05-Jul-2024 Anacura acquires OHMX.bio, adding multi-omics for drug discovery and diagnostics to its services. Anacura
03-Jul-2024 BC Platforms Announces Appointment of New Chairman, Alex Dickinson BC Platforms
03-Jul-2024 LEO Pharma, Allergy UK and Expert Taskforce Uncover the Real Burden of Living with Chronic Hand Eczema (CHE) in New Report LEO Pharma
03-Jul-2024 Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China Medigene AG
03-Jul-2024 Pneumagen Highlights Broad-Spectrum Antiviral Activity of First-in-Class Intranasal Drug Neumifil in New Publication Pneumagen
03-Jul-2024 Agreement to Explore Optimer Vehicles for Targeted Delivery of siRNA Aptamer Group plc
03-Jul-2024 Syncona portfolio company Beacon Therapeutics raises $170 million in a Series B financing Syncona Limited
02-Jul-2024 Almirall launches Act4Impact – its updated sustainability strategy setting ambitious targets for 2030 Almirall
02-Jul-2024 Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout Sob
02-Jul-2024 Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325 Mission Therapeutics
02-Jul-2024 ramarketing strengthens AI capabilities with key leadership appointments ramarketing
02-Jul-2024 Clinigen appoints Fernando Ballester as Chief Financial Officer Clinigen